ProShares Ultra Silver (AGQ): just the beginning folks, break out the...

just the beginning folks, break out the Latte's,

trunkmonk · 2025-03-05T00:18:35.9100000Z

just the beginning folks, break out the Latte's, long way to go

Play Episode

5min

Proactive - Interviews for investors

Ilika CEO Graeme Purdy on 50Ah Goliath EV battery prototype milestone; scaling up

Ilika PLC (AIM:IKA, OTCQX:ILIKF) CEO Graeme Purdy joined Proactive's Stephen Gunnion with details about the company's latest milestone—the successful prototyping of its 50Ah Goliath EV battery. This marks a significant leap from the previous 2Ah prototype, representing a 25-fold increase in capacity. Purdy highlighted the importance of scaling up production to meet industry requirements. "We need to make sure that we've got reproducibility. What industry needs is not just a few successful cells but large-scale, reliable production," he said. Ilika has benefited from £2.8 million in grant funding through the Faraday Battery Challenge, which Purdy noted has effectively doubled the impact of investor funding. In parallel, Ilika has also demonstrated its manufacturing process at a giga-scale setting through a partnership with the UK Battery Industrialisation Centre (UKBIC). Looking ahead, the company plans to complete its 1.5MWh per year pilot line with automated equipment. Key upcoming milestones include releasing P1.5 prototypes in the summer and the full P2 release by year-end. Stay tuned for more updates on Ilika’s Goliath program. For more interviews with industry leaders, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications for future updates. #IlikaPLC #EVBatteries #SolidStateBatteries #BatteryTechnology #EnergyStorage #RenewableEnergy #ElectricVehicles #BatteryInnovation #TechInvesting #ProactiveInvestors

Proactive - Interviews for investors

North Bay Resources ships gold concentrate as mill optimization advances

North Bay Resources has reached a key milestone in its gold production efforts, successfully completing a test shipment of 327 lbs. of gold concentrate from the Bishop Gold Mill to Just Refiners in Reno, NV. CEO Jared Lazerson shared the update with Steve Darling from Proactive, emphasizing the company’s progress in optimizing mill operations and enhancing gold recovery from its Fran Gold Property. The February ore processing runs yielded approximately 2.44 troy ounces of contained gold from 10 tons of ore, equating to a recovered gold grade of 0.24 ounces per ton. Additionally, 0.1 ounces of contained gold remains in low-grade concentrate at the mill. Current estimates place overall recovery at 50%, with gravity-recoverable gold recovery at 70%. Metallurgical testing suggests that up to 67% gravity recovery can be achieved, with an additional 30% recoverable through flotation. To further enhance recovery rates, North Bay Resources is bringing its flotation circuit online, targeting very fine gold and gold in quartz that is not efficiently captured by existing gravity separation methods. This upgrade is expected to boost overall gold recovery by up to 30% as the company continues to refine its extraction process. With ongoing improvements to both its gravity and flotation circuits, North Bay Resources is poised to significantly enhance gold recovery and production efficiency at the Bishop Gold Mill, marking an important step in its broader operational strategy. #proactiveinvestors #northbayresourcesinc #otc #nbri #PlatinumConcentrate #NorthBayResources #MiningNews #CaliforniaGold #JaredLazerson #GoldRush #ProactiveInvestors #PreciousMetals #MiningUpdates ---#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Proactive - Interviews for investors

BioHarvest Sciences achieves breakthrough in Liver health with Olive Cell compound

BioHarvest Sciences has announced a significant advancement in liver health research, with new in vitro test results demonstrating the efficacy of its proprietary Olive Cell compound in reducing fat accumulation in human liver cells. CEO Ilan Sobel shared the news with Steve Darling from Proactive, highlighting the compound’s potential in addressing non-alcoholic fatty liver disease (NAFLD)—a condition that affects 30–40% of U.S. adults and currently has limited FDA-approved treatment options. The latest studies revealed that the Olive Cell compound mitigated fat accumulation in both a liver steatosis model and experimental models of liver fibrosis. Additionally, it reduced collagen type 1 levels in XL-2 cells, a key marker of fibrosis progression, further reinforcing its therapeutic potential. BioHarvest attributes these promising results to the compound’s high levels of Verbascoside, a bioactive polyphenol with anti-inflammatory and antioxidant properties. Looking ahead, the company plans to conduct further studies in 2025, with the goal of launching Olive Cell as a nutraceutical product in 2026. Meanwhile, BioHarvest is also exploring pharmaceutical partnerships to bring the compound to market through a CDMO (Contract Development and Manufacturing Organization) model. With these groundbreaking findings, BioHarvest Sciences is positioning itself at the forefront of liver health innovation, offering a potential new solution for millions affected by NAFLD and liver fibrosis. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Proactive - Interviews for investors

Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data

Immunic Therapeutics chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company's strong presence at the 10th annual ACTRIMS Forum, where it presented two key posters on multiple sclerosis (MS). He highlighted that Immunic’s investigational drug, vidofludimus calcium, has potential neuroprotective properties that may benefit both relapsing and progressive MS patients. One of the posters examined baseline characteristics of past progressive MS trials and contrasted them with Immunic’s CALLIPER trial, designed for non-relapsing patients with minimal inflammatory activity. The second poster explored preclinical data on the drug’s mechanism of action, emphasizing its potential to target activated microglia and support neuron survival. Muehler noted significant engagement from the MS community at ACTRIMS, with many keenly anticipating the CALLIPER trial’s readout in April. “It’s really one of the very few late-stage drugs with a potential neuroprotective effect,” he said, adding that the data could provide new hope for progressive MS patients who currently have limited treatment options. Stay tuned for more updates on Immunic’s progress. For more interviews, subscribe to Proactive’s YouTube channel, like this video, and turn on notifications! #ImmunicTherapeutics #MSResearch #Neuroprotection #CALLIPERTrial #MultipleSclerosis #Biotech #DrugDevelopment #ClinicalTrials #MedicalBreakthrough #ACTRIMS

Followers	211
Posts	23026
Boards Moderated	2
Alias Born	04/17/2006

Volume:	2,209,560
Day Range:	44.545 - 45.87
Bid:
Ask:
Last Trade Time:	4:00:00 PM EDT
Total Trades:	8,258

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

AGQ Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free